TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05305885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
Study: NCT05382312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIFAFOUR e-275
Description: RIFAFOUR e-275 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 will be administered.
Study: NCT05354778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Corticosteroid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline only
Study: NCT05021679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AMP Implementation
Description: Each study site will implement the Johns Hopkins AMP program at different times. The AMP program includes nursing staff training on the goals of AMP, how to complete mobility-focused outcome measures, set mobility goals, and to safely mobilize/ambulate patients. The AMP program also includes embedding these outcome measures and mobility goals into electronic medical records and producing weekly/monthly reports that show how often nursing staff score patient mobility and help patients meet daily activity goals.
Study: NCT05871944

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KAlternborn Joint Mobilization
Description: This is a join mobilization technique to reduce the joint stiffness and help in improving joint range of motion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post stretch Facilitation Technique
Description: This is a PNF techniques used to relax the muscles and help in getting more free range of restricted joint
Study: NCT05808868

Intervention type: OTHER
Intervention: Screening
Description: The detailed management is not different from that usually practiced in our department.~Each patient benefits from an ENT consultation where an interrogation is carried out concerning the sleep disorders, the answer to the usual questionnaires screening for sleep disorders, a detailed ENT clinical examination including a nasofibroscopy. Each patient then benefits from a sleep recording by ventilatory polygraph.
Study: NCT06479967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The VR glasses group
Description: The Virtual Reality glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine The VR glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine After the SPT, the VR glasses group took a 1-minute break from watching videos and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the VR glasses group continued watching cartoon

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the music group
Description: The music group listened to classical piano \&#34;The Best of Chopin.\&#34; After the music group took a 1-minute break from listening to music, and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the music group continued to listen to the music. During the SPT evaluation, the music group took a 1-minute break from listening to music at 5, 10, and 15 minutes, and the child evaluated the level of itching from 1 to 10.
Study: NCT05216861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demand and ability protocol
Description: The intervention consists of a structured conversation between the patient and his immediate manager under the guidance of licensed medical staff (in this case REKO) with knowledge of the requirements of the patient's work and his/her current functional ability. The intervention takes about 90 minutes excluding preparation time for REKO.~DAP consider the following domains; 1) mental and cognitive ability, 2) basic skills and social ability, 3) tolerance for physical conditions, 4) ability to work dynamically, 5) ability to work statically and 6) to be able to work certain times.~Based on the above domains, a structured review is made of the balance between requirements and function in current work in order to identify possible adaptations and measures at the workplace. During the intervention, the work requirements and the patient's function/ability are identified on a three-point scale and in domains where there is thus an imbalance adjustments or changed tasks are identified.

Intervention type: OTHER
Group type: OTHER
Intervention: Collaborative interventions as usual
Description: The rehabilitation coordinator conduct collaborative interventions as usual with patient and employer. This might be through phone calls are unstructured meetings.
Study: NCT06054009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT
Description: In Study 1: x4 CBT sessions addressing cognitive appraisals of dissociation. In Study 2: x4 CBT sessions addressing rumination/worry. In Study 3: x4 CBT sessions addressing affect intolerance.
Study: NCT06166693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINDLiNG Digital Mental Health Intervention
Description: The intervention was delivered on an online platform set up separately for the study, which was accessible via the web browser and application. The psychological intervention program for maladaptive personality traits (Mindling) is based on the principles of CBT, psychological schema therapy, acceptance-commitment therapy, and mindfulness-based cognitive therapy, and is aimed primarily at adults to prevent and overcome psychological difficulties
Study: NCT05857787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound with nerve track function
Description: The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use this feature to educate subjects before seeking brachial plexus and median nerve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound without nerve track function
Description: The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use ultrasound alone without this feature to educate subjects before seeking brachial plexus and median nerve.
Study: NCT05043051

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagal stimulation
Description: Vagal stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham vagal stimulation
Study: NCT06323733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France. Each session will last 1 hour under the supervision of physiotherapists. Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of
Study: NCT06462352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navicam SB capsule
Description: Exploration of the small bowel by Navicam SB endoscopic capsule.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pillcam SB3
Description: Exploration of the small bowel by Pillcam SB3 endoscopic capsule.
Study: NCT04571645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat
Description: Dociparstat is a glycosaminoglycan derived from porcine heparin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 0.9% Normal Saline
Study: NCT05883657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condition 1 : Prototypes (816-v1) every weeks
Description: Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condition 2 : Prototypes (816-v1) every two weeks
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study: NCT06332079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 166Holmium TARE
Description: 166Ho-TARE treatment comprises of two hospital visits: one for a work-up procedure and another for the therapy procedure, with usually a 1-2 weeks interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Target agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Target agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Chemotherapy
Study: NCT05403853

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venepuncture
Description: Venous blood draw

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fingerstick
Description: Capillary Blood Draw
Study: NCT06332079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Target agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemotherapy
Study: NCT05912686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin 20mg
Description: The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
Study: NCT05320705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra Operative Dexmedetomidine
Description: Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra Operative Dexmedetomidine
Description: Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
Study: NCT06382246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise snacks
Description: Bodyweight-style exercise snacks lasting 1-minute each performed with vigorous effort 4 times per day on two consecutive days.
Study: NCT06301997

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ZAX.1400.P03
Description: ZAX.1400.P03, applied twice daily for 3 weeks after enrolment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, applied twice daily for 3 weeks after enrolment
Study: NCT05499390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Subjects receive AK112 intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Subjects receive Pembrolizumab intravenously.
Study: NCT06495931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780 tablets
Description: HRS-1780 tablets, three times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20033 tablets
Description: HR20033 tablets, nine times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablets
Description: HRS-7535 tablets ，three times or nine times
Study: NCT06328530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
Study: NCT05348291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilation tubes
Description: Transtympanic pressure equalising devices.
Study: NCT06398067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vietnamese Self-Help Plus (vSH+)
Description: vSH+ is a stress management program delivered through four 75-minute sessions. It includes the five core SH+ skills. Healthcare workers (nurses and social workers) function as lead facilitators (called 'HW Facilitators') and cancer survivors as co-facilitators (called 'Peer Facilitators').

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 'Doing What Matters in Times of Stress' (DWM) Guide
Description: An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Doing What Matters in Times of Stress' (DWM) Guide
Description: An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.
Study: NCT04537377

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VTX-801
Description: The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).~After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels.
Study: NCT05323448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Group
Description: During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARISTA
Description: During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent). Before surgical wound closure, the corresponding amount of ARISTA-AH will be applied to completely cover the bleeding site :~* 5g for 5 to 8 instrumented vertebra~* 10g fo 9 or more instrumented vertebra
Study: NCT04871711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream\> except that it does not contain any active ingredient.
Study: NCT06436950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical phrenic nerve stimulation (TEPNS)
Description: TEPNS is conducted twice a day for consecutive 5 days. Electrodes are applied to bilateral neck skin which phrenic nerve runs underneath.
Study: NCT06328530

Intervention type: OTHER
Group type: OTHER
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
Study: NCT04859400

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB)
Description: The whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB) is ingested once daily, preferably either in the evening before going to bed or within two hours after having finished exercising.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized nutritional program
Description: During at least two personal counseling meetings with a dietician, the patient's diet is assessed and individual nutritional interventions - based on the personal needs and individual preferences of the patient - are developed. The overall goal is to optimize protein an energy intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized exercise program
Description: In at least two personal counseling meetings with a physiotherapist, the patient's individual training plan is compiled and agreed upon (mainly including strength, endurance and balance exercises). The patient then exercises at home and records the trainings with the app.
Study: NCT06569602

Intervention type: DEVICE
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricuspid valve through a transcatheter approach
Study: NCT05025423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet [Venclexta]
Description: Sequential dose levels for Venetoclax dependent on patient response. Fixed doses of 375 mg/m2 rituximab. Fixed dose of Bendamustine 90 mg/m2 added for those with continued PR at Cycle 8
Study: NCT06487000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo EC-18
Description: oral administration, QD
Study: NCT06031584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.
Study: NCT04709900

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT angiography, FFR-CT and stress CT myocardial perfusion
Description: The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
Study: NCT04932876

Intervention type: BIOLOGICAL
Intervention: SARS - COV 2 VACCINE
Description: Vaccination for SARS - COV 2

Intervention type: BIOLOGICAL
Intervention: SARS - COV 2 VACCINE
Description: Vaccination for SARS - COV 2
Study: NCT06487000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EC-18
Description: oral administration, QD
Study: NCT04545151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil SR 120 mg
Description: For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily